Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Gilead Sciences, Inc.

Capitalization 180B 156B 141B 135B 246B 16,644B 254B 1,683B 668B 7,952B 676B 662B 28,704B P/E ratio 2026 *
20.1x
P/E ratio 2027 * 17.4x
Enterprise value 185B 160B 145B 138B 252B 17,069B 261B 1,726B 685B 8,156B 694B 679B 29,438B EV / Sales 2026 *
6.12x
EV / Sales 2027 * 5.53x
Free-Float
99.9%
Yield 2026 *
2.24%
Yield 2027 * 2.48%
1 day-0.54%
1 week+0.05%
Current month-2.51%
1 month-4.35%
3 months+20.61%
6 months+26.77%
Current year+18.31%
1 week 143.48
Extreme 143.485
149.38
1 month 142.77
Extreme 142.77
156.01
Current year 116.88
Extreme 116.88
157.29
1 year 93.37
Extreme 93.37
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 60 2019-02-28
Director of Finance/CFO 56 2019-10-31
Chief Tech/Sci/R&D Officer 64 2025-01-01
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Change 5d. change 1-year change 3-years change Capi.($)
-0.54%+0.05%+27.39%+82.65% 180B
-2.26%-0.61%+18.91%+210.22% 873B
-0.39%+1.01%+48.63%+59.65% 583B
-1.01%-3.00%+6.28%+50.54% 398B
-3.58%-9.47%+3.55%+20.69% 324B
-0.83%-2.78%+23.30%+34.27% 297B
-0.33%-3.19%+25.47%+61.94% 294B
-0.26%-0.14%+24.17%+7.63% 287B
-2.61%+0.05%+17.69%+61.40% 198B
-1.61%+0.94%+4.47%-31.81% 153B
Average -1.08%-1.71%+19.98%+55.72% 358.81B
Weighted average by Cap. -0.78%-1.63%+22.02%+83.04%

Financials

2026 *2027 *
Net sales 30.19B 26.19B 23.68B 22.61B 41.12B 2,787B 42.56B 282B 112B 1,332B 113B 111B 4,806B 32.01B 27.77B 25.11B 23.98B 43.61B 2,956B 45.14B 299B 119B 1,412B 120B 118B 5,098B
Net income 9.06B 7.86B 7.1B 6.78B 12.34B 836B 12.77B 84.53B 33.57B 399B 33.98B 33.26B 1,442B 10.01B 8.69B 7.85B 7.5B 13.64B 925B 14.12B 93.48B 37.12B 442B 37.58B 36.78B 1,594B
Net Debt 4.61B 4B 3.62B 3.45B 6.28B 426B 6.5B 43.04B 17.09B 203B 17.3B 16.93B 734B -3.1B -2.69B -2.43B -2.32B -4.22B -286B -4.37B -28.93B -11.49B -137B -11.63B -11.38B -493B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-03-12 145.21 $ -0.54% 7,006,787
26-03-11 146.00 $ -1.72% 5,552,156
26-03-10 148.56 $ +1.32% 5,098,461
26-03-09 146.63 $ +1.88% 5,210,502
26-03-06 143.93 $ -0.83% 4,921,313
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
145.21USD
Average target price
157.43USD
Spread / Average Target
+8.41%

Quarterly revenue - Rate of surprise

SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW